Data topics

When pharma brands strike major deals, they don’t just gain access—they inherit complex tradeoffs. From navigating volume vs. margin to managing payer fatigue, these tradeoffs shape strategy long after contracts are signed. This blog breaks down five recurring tensions in market access and shows how AI-powered analytics helps commercial and HEOR teams model scenarios, simulate outcomes, and move from rigid strategy to adaptive execution.

With the FDA’s landmark approval of CAR-T therapies like Abecma and Carvykti as earlier-line treatments, the commercial landscape is shifting rapidly. This blog explores the next phase of CAR-T market access and the analytics brand teams need to navigate it. Learn how to forecast pull-through, identify high-opportunity accounts, and guide sales execution using real-world data, segmentation strategies, and AI-powered insights. From payer dynamics to provider referral patterns, find out what it takes to win in a competitive, high-cost therapeutic space.

Faster drug approvals are coming. Here's how field sales, market access, and brand teams must adapt—and why AI analytics is no longer optional.

Market access teams at pharmaceutical & life science organizations are critical to commercial success. Here's how AI-powered approaches can help.